Bispecific Antibodies

Bispecific antibodies
#Bispecific Antibodies #Collaboration #Dualitas Therapeutics #Roche

Roche and Dualitas Therapeutics agree $1b bispecific antibodies deal

Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases.  Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for a potential total… Read More

#Business & Investment #News

Bispecific antibodies
#Bispecific Antibodies #European Commission #Johnson & Johnson #Myeloma #Oncology

EC okays immunotherapy double regimen for multiple myeloma

The European Commission (EC) has approved Johnson & Johnson’s Tecvayli (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care.  The indication extension in combination with daratumumab is approved for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least… Read More

#News #Regulatory

Bispecific antibodies
#Bispecific Antibodies #Boulevard Bio #Fundraising #Monoclonal antibodies #Start-ups

Multi-specific antibody company launches with $65 million

Boulevard Bio has emerged from stealth with $65 million from founding investor Deerfield Management and early Phase I healthy volunteer data for lead candidate BLVD101.   Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), Boulevard's approach is grounded in a deep… Read More

#Business & Investment #News

Medical laboratory
#Bispecific Antibodies #Cancer research #Clinical trial

Mestag doses first patient in treatment for solid tumours 

Mestag Therapeutics has dosed the first patient in its Phase I trial evaluating a novel therapeutic strategy to treat solid tumours.  MST-0312 is a bispecific antibody designed to activate lymphotoxin-beta receptor (LTBR) in the tumour microenvironment to induce the formation of tertiary lymphoid structures (TLS) and associated high… Read More

#Cancer Research #News

Bispecific antibodies
#Bispecific Antibodies #Cell line development #Whitepaper

A practical guide to robust bispecific antibody cell line development

In this new whitepaper, discover how ProBio accelerates bispecific antibody development with optimised cell line strategies. This guide highlights proven methods such as two-vector expression systems and NGS‑enabled clone selection to improve purity, productivity, and manufacturing robustness. You will learn: How to reduce bispecific antibody impurities through chain‑ratio optimisation Methods… Read More

#News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

Non-Hodgkins lymphoma
#Bispecific Antibodies #Follicular lymphoma #National Institute for Health and Care Excellence (NICE)

NICE recommends first bispecific antibody to treat lymphoma 

The National Institute for Health and Care Excellence (NICE) has recommended the first bispecific antibody for the treatment of follicular lymphoma (FL).  Tepkinly (epcoritamab), developed by biopharmaceutical company AbbVie, has been recommended to the NHS as an option to treat adult patients with FL whose cancer has returned or who have… Read More

#News #Regulatory

#Acute inflammatory conditions #Autoimmune disease #Bispecific Antibodies #Collaboration #Earendil Labs #Sanofi

Sanofi and Earendil agree $2.56b bispecific antibodies deal

Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programmes.  Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration.  According to the agreement Earendil Labs will receive up to $160 million in upfront… Read More

#Business & Investment #News

Bispecific antibodies
#Bispecific Antibodies #Celldex #Fibrosis #Monoclonal antibodies #Phase I trial

CDX-622 demonstrates sustained mast cell inhibition

Celldex has revealed positive data from the ongoing Phase I study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis.  These pathways are mast cell depletion via stem cell factor (SCF) starvation and neutralisation of the alarmin thymic stromal… Read More

#News

Bispecific antibodies
#Bispecific Antibodies #Genmab #Head and neck cancer #Mergers and acquisitions #Oncology

Genmab to acquire Merus for approximately $8 billion

Genmab has agreed to acquire Merus, a clinical-stage biotechnology company with a late-stage breakthrough therapy asset called petosemtamab, which is in Phase III development.  Genmab will pay $97.00 per share in an all-cash transaction representing a transaction value of approximately $8 billion.   The proposed acquisition of Merus is expected to… Read More

#Business & Investment #News

Antibodies
#Bispecific Antibodies #Financing

Dualitas Therapeutics to develop next-gen specific antibodies

Biotechnology company Dualitas Therapeutics has launched from stealth with a $65 million (£48 million) Series A financing round to develop next-generation bispecific antibodies (BsAbs).  The company’s financing is co-led by Versant Ventures and Qiming Venture Partners USA, with participation from founding investor SV Health Investors and new… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Cancer research #Solid tumours #SOTIO

The challenges in solid tumour targeting with bispecific ADCs

Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More

#Cancer Research #Exclusive Content

B-cells in multiple myeloma
#Acquisition #Bispecific Antibodies #Dren Bio #Finance #Immunology #Sanofi

Bi-specific antibody acquisition broadens immunology pipeline

Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More

#Business & Investment #News

Bispecific antibodies
#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

Download the Article: The discovery and evolution of antibody formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This Article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent F1P HF as an alternative strategy for isolating… Read More

#News

#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Resources